Helping African American kidney transplant patients keep their transplants working longer
Multifaceted Intervention to Improve Graft Outcome Disparities in African American Kidney Transplants (MITIGAAT)
['FUNDING_R01'] · MEDICAL UNIVERSITY OF SOUTH CAROLINA · NIH-11120974
This project uses technology-enabled medication monitoring plus blood pressure and diabetes support to help African American kidney transplant recipients protect their transplanted kidneys.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MEDICAL UNIVERSITY OF SOUTH CAROLINA (nih funded) |
| Locations | 1 site (CHARLESTON, UNITED STATES) |
| Trial ID | NIH-11120974 on ClinicalTrials.gov |
What this research studies
You would be offered a package of tools including real-time medication monitoring, closer tacrolimus level tracking, and extra support to control blood pressure and diabetes. The team combines technology (such as medication sensors and remote monitoring) with clinic follow-up to detect missed doses, high drug level variability, and uncontrolled blood pressure or glucose and then intervene. This work builds on small pilot and randomized trials that improved blood pressure and diabetes control and showed real-time adherence monitoring is acceptable to patients. The overall aim is to reduce late rejection and graft loss that occur more often in African American transplant recipients.
Who could benefit from this research
Good fit: African American adults who have received a kidney transplant—especially those at least two years post-transplant or with challenges controlling blood pressure, diabetes, or medication adherence—are the intended candidates.
Not a fit: People without a kidney transplant, non–African American recipients outside the study criteria, or patients with early post-transplant problems not targeted by this intervention may not receive direct benefit.
Why it matters
Potential benefit: If successful, this approach could lower late rejection and graft loss in African American kidney transplant recipients by improving medication adherence and control of blood pressure and diabetes.
How similar studies have performed: Prior pilot work and two randomized trials from the team showed improved blood pressure and diabetes control and high acceptance of real-time medication monitoring, though large-scale impact on graft survival remains unproven.
Where this research is happening
CHARLESTON, UNITED STATES
- MEDICAL UNIVERSITY OF SOUTH CAROLINA — CHARLESTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TABER, DAVID J. — MEDICAL UNIVERSITY OF SOUTH CAROLINA
- Study coordinator: TABER, DAVID J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.